‪Jesús San Miguel ORCID 0000-0002-9183-4857‬

Citée par

	Toutes	Depuis 2019
Citations	146472	60288
indice h	169	106
indice i10	1085	663

13000

6500

3250

9750

19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024452 555 724 954 1263 1429 1629 2108 2527 2989 3398 4290 5069 5511 6678 6846 7065 8812 9114 9397 9495 11159 12847 11124 11595 3772

Accès public

Tout afficher

227 articles

40 articles

disponibles

non disponibles

Sur la base des exigences liées au financement

Coauteurs

MV MateosSalamancaAdresse e-mail validée de usal.es
Meletios Athanasios DimopoulosNational and Kapodistrian University of Athens, School of MedicineAdresse e-mail validée de med.uoa.gr
joaquin martinez lopezComplutense UniversityAdresse e-mail validée de ucm.es
Antonio PalumboUniversità di Torino; Torino ItalyAdresse e-mail validée de unito.it
Hartmut GoldschmidtUniversitätsklinikum HeidelbergAdresse e-mail validée de med.uni-heidelberg.de
philippe Moreauhematology department nantes franceAdresse e-mail validée de chu-nantes.fr
Michele CavoProfessor of HematologyAdresse e-mail validée de unibo.it
Prof. Dr. Heinz LudwigWilhelminen Cancer Research InstituteAdresse e-mail validée de aon.at
Robert Z. OrlowskiThe University of Texas MD Anderson Cancer CenterAdresse e-mail validée de mdanderson.org
Mario BoccadoroEmeritus Professor of Hematology, University of Torino, ItalyAdresse e-mail validée de unito.it
Vincent RajkumarMayo ClinicAdresse e-mail validée de mayo.edu
Saad Z. UsmaniChief of Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NYAdresse e-mail validée de mskcc.org
Niels van de DonkAssociate Professor of Hematology, VU University Medical CenterAdresse e-mail validée de vumc.nl
Evangelos TerposNational and Kapodistrian University of AthensAdresse e-mail validée de med.uoa.gr
Shaji Kunnathu KumarMayo ClinicAdresse e-mail validée de mayo.edu
Darrell J WhiteDalhousie University, MedicineAdresse e-mail validée de dal.ca
Andrew SpencerProfessor of HaematologyAdresse e-mail validée de monash.edu
A. keith stewartuniversity health networkAdresse e-mail validée de uhn.ca
Torben PlesnerVejle Hospital and University of Southern DenmarkAdresse e-mail validée de rsyd.dk
Miguel SanzHospital Universitario La FeAdresse e-mail validée de uv.es

Suivre

Jesús San Miguel ORCID 0000-0002-9183-4857

Director de Medicina Clínica y Traslacional de la Universidad de Navarra, Director Médico de la CUN

Adresse e-mail validée de unav.es - Page d'accueil

Hematology Hematotherapy Multiple myeloma


Titre Trier par citations Trier par année Trier par titre	Citée par Citée par	Année
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ... The lancet oncology 15 (12), e538-e548, 2014	4957	2014
International staging system for multiple myeloma PR Greipp, JS Miguel, BGM Durie, JJ Crowley, B Barlogie, J Bladé, ... Journal of clinical oncology 23 (15), 3412-3420, 2005	3700	2005
International uniform response criteria for multiple myeloma BGM Durie, JL Harousseau, JS Miguel, J Blade, B Barlogie, K Anderson, ... Leukemia 20 (9), 1467-1473, 2006	3441	2006
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma PG Richardson, P Sonneveld, MW Schuster, D Irwin, EA Stadtmauer, ... New England journal of medicine 352 (24), 2487-2498, 2005	3085	2005
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ... The lancet oncology 17 (8), e328-e346, 2016	2472	2016
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma JF San Miguel, R Schlag, NK Khuageva, MA Dimopoulos, O Shpilberg, ... New England Journal of Medicine 359 (9), 906-917, 2008	2456	2008
Revised international staging system for multiple myeloma: a report from International Myeloma Working Group A Palumbo, H Avet-Loiseau, S Oliva, HM Lokhorst, H Goldschmidt, ... Journal of clinical oncology 33 (26), 2863, 2015	2143	2015
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia XS Puente, M Pinyol, V Quesada, L Conde, GR Ordóñez, N Villamor, ... Nature 475 (7354), 101-105, 2011	1875	2011
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma M Dimopoulos, A Spencer, M Attal, HM Prince, JL Harousseau, ... New England Journal of Medicine 357 (21), 2123-2132, 2007	1818	2007
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma AK Stewart, SV Rajkumar, MA Dimopoulos, T Masszi, I Špička, A Oriol, ... New England Journal of Medicine 372 (2), 142-152, 2015	1581	2015
Daratumumab, lenalidomide, and dexamethasone for multiple myeloma MA Dimopoulos, A Oriol, H Nahi, J San-Miguel, NJ Bahlis, SZ Usmani, ... New England Journal of Medicine 375 (14), 1319-1331, 2016	1576	2016
Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease JJM Van Dongen, EA Macintyre, JA Gabert, E Delabesse, V Rossi, ... Leukemia 13 (12), 1901-1928, 1999	1535	1999
Elotuzumab therapy for relapsed or refractory multiple myeloma S Lonial, M Dimopoulos, A Palumbo, D White, S Grosicki, I Spicka, ... New England Journal of Medicine 373 (7), 621-631, 2015	1501	2015
Idecabtagene vicleucel in relapsed and refractory multiple myeloma NC Munshi, LD Anderson Jr, N Shah, D Madduri, J Berdeja, S Lonial, ... New England Journal of Medicine 384 (8), 705-716, 2021	1439	2021
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study P Moreau, H Pylypenko, S Grosicki, I Karamanesht, X Leleu, ... The lancet oncology 12 (5), 431-440, 2011	1173	2011
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1 SV Rajkumar, JL Harousseau, B Durie, KC Anderson, M Dimopoulos, ... Blood, The Journal of the American Society of Hematology 117 (18), 4691-4695, 2011	1124	2011
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia RG Owen, SP Treon, A Al-Katib, R Fonseca, PR Greipp, ML McMaster, ... Seminars in oncology 30 (2), 110-115, 2003	1103	2003
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders A Dispenzieri, R Kyle, G Merlini, JS Miguel, H Ludwig, R Hájek, ... Leukemia 23 (2), 215-224, 2009	1049	2009
Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma A Palumbo, SV Rajkumar, MA Dimopoulos, PG Richardson, J San Miguel, ... Leukemia 22 (2), 414-423, 2008	1021	2008
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and … RA Kyle, BGM Durie, SV Rajkumar, O Landgren, J Bladé, G Merlini, ... Leukemia 24 (6), 1121-1127, 2010	1015	2010

Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.

Articles 1–20

Nombre de citations par an

Citations en double

Citations fusionnées

Ajouter les coauteursCoauteurs

Suivre

Citée par

Coauteurs